Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 69 for “"hematological malignancy"”.

  1. Machine Learning Techniques for Augmenting Hematological Malignancy Diagnosis

    … methods to enhance the diagnostic workflow of hematological malignancies, particularly in cytogenetics and clinical flow cytometry. The recent advancements in the field of ML provide a unique opportunity to develop, adapt, and evaluate algorithms for augmenting the hematopathology diagnostic …

    utswmed Repository record for Machine Learning Techniques for Augmenting Hematological Malignancy Diagnosis (opens in a new tab)

  2. An Investigation of 53BP1 in Multiple Myeloma

    … multiple myeloma is the second most common hematological malignancy, and as of yet it remains incurable. Although many therapeutic advances have been made in the recent past, there is still room for improvement in the treatment of myeloma. Here, using CRISPR/Cas9 genome editing, we show that …

    calgary Repository record for An Investigation of 53BP1 in Multiple Myeloma (opens in a new tab)

  3. CHARACTERIZING FUNCTIONAL ROLES AND CLINICAL IMPLICATIONS OF SUPER ENHANCER ASSOCIATED GENES IN MULTIPLE MYELOMA

    Multiple myeloma (MM) is a hematological malignancy arising from plasma cells. Despite extensive genetic characterization, it remains poorly understood how chromatin rewiring of the regulatory elements contributes to MM progression. Super enhancers (SEs) are large clusters of enhancers with …

    nus Repository record for CHARACTERIZING FUNCTIONAL ROLES AND CLINICAL IMPLICATIONS OF SUPER ENHANCER ASSOCIATED GENES IN MULTIPLE MYELOMA (opens in a new tab) Download file for CHARACTERIZING FUNCTIONAL ROLES AND CLINICAL IMPLICATIONS OF SUPER ENHANCER ASSOCIATED GENES IN MULTIPLE MYELOMA (opens in a new tab)

  4. IDENTIFICATION OF G9A AS A THERAPEUTICALLY TARGETABLE DRIVER OF MULTIPLE MYELOMA TUMORIGENESIS

    Multiple myeloma (MM) is an incurable leading hematological malignancy with highly disturbed epigenetic landscape. G9a, a histone methyltransferase, was found to promote disease progression, proliferation and metastasis via different mechanisms in several cancers, while the role of G9a in MM …

    nus Repository record for IDENTIFICATION OF G9A AS A THERAPEUTICALLY TARGETABLE DRIVER OF MULTIPLE MYELOMA TUMORIGENESIS (opens in a new tab) Download file for IDENTIFICATION OF G9A AS A THERAPEUTICALLY TARGETABLE DRIVER OF MULTIPLE MYELOMA TUMORIGENESIS (opens in a new tab)

  5. TRANSCRIPTIONAL REGULATORY PROGRAM CONTROLLED BY MYB IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

    … T-cell acute lymphoblastic leukemia (T-ALL), a hematological malignancy originating from T-cell precursors. Here, we demonstrate that MYB plays a crucial role by regulating genes essential for T-ALL pathogenesis. Integrative analysis reveals a long MYB isoform, ENST00000367814.8, which is …

    nus Repository record for TRANSCRIPTIONAL REGULATORY PROGRAM CONTROLLED BY MYB IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (opens in a new tab) Download file for TRANSCRIPTIONAL REGULATORY PROGRAM CONTROLLED BY MYB IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (opens in a new tab)

  6. Activities of the cytokine receptor CD137 in multiple myeloma

    Multiple myeloma is an incurable hematological malignancy derived from B cells, and characterized by bone destruction and multiple organ dysfunctions. CD137 and its ligand are members of the Tumor Necrosis Factor (TNF) Receptor and TNF superfamilies, respectively. CD137 enhances proliferation and …

    nus Repository record for Activities of the cytokine receptor CD137 in multiple myeloma (opens in a new tab) Download file for Activities of the cytokine receptor CD137 in multiple myeloma (opens in a new tab)

  7. Approaches to targeted therapy in multiple myeloma

    Multiple Myeloma (MM) is the second most common hematological malignancy, and although patient outcomes have significantly improved since the introduction of autologous stem cell transplantation (ASCT) and novel pharmacological agents such as immunomodulators (IMID), proteasome inhibitors (PI), and …

    bu Repository record for Approaches to targeted therapy in multiple myeloma (opens in a new tab)

  8. TAC Engineered γδ T cells for Multiple Myeloma

    … have had unprecedented success in treating hematological malignancies. However, their use is limited by expensive treatment costs – priced at approximately $500,000 CAD for a single-dose of CAR-T cell therapy. γδ T cells are a candidate for allogeneic engineered T cell therapies, which can …

    mcmaster Repository record for TAC Engineered γδ T cells for Multiple Myeloma (opens in a new tab)

  9. REQUIREMENT OF TP73 IN CANCER CELL MAINTENANCE AND GENETIC ALTERATIONS EVOLVING FROM ITS INTRAGENIC SUPER-ENHANCER

    … leukemia/lymphoma (ATL), a genetically complex hematological malignancy, we selected genes that harbor recurrent SVs within their super-enhancers. This approach highlighted TP73, which is highly activated under the control of a super-enhancer and is required for ATL cell maintenance in vitro and …

    nus Repository record for REQUIREMENT OF TP73 IN CANCER CELL MAINTENANCE AND GENETIC ALTERATIONS EVOLVING FROM ITS INTRAGENIC SUPER-ENHANCER (opens in a new tab) Download file for REQUIREMENT OF TP73 IN CANCER CELL MAINTENANCE AND GENETIC ALTERATIONS EVOLVING FROM ITS INTRAGENIC SUPER-ENHANCER (opens in a new tab)

  10. INTERROGATING THE ROLE OF PROTEIN S-GLUTATHIONYLATION IN ACUTE MYELOID LEUKEMIA

    … cancer biology. Acute myeloid leukemia (AML), a hematological malignancy with poor five-year survival rate, is highly dependent on GSH metabolism, highlighting the need to investigate protein S-glutathionylation in AML pathogenesis. Here, we demonstrate that the reversibility of protein …

    toronto-retro Repository record for INTERROGATING THE ROLE OF PROTEIN S-GLUTATHIONYLATION IN ACUTE MYELOID LEUKEMIA (opens in a new tab)

  11. How does leukemia disrupt hematopoiesis?

    <p>Acute myeloid leukemia (AML) is an aggressive hematological malignancy which, if left untreated, results in complete bone marrow (BM) failure characterised by anemia, neutropenia and thrombocytopenia. Although the symptoms of AML can occur at low levels of disease burden, their manifestation is …

    oxford Repository record for How does leukemia disrupt hematopoiesis? (opens in a new tab)

  12. NON-GENETIC MECHANISMS OF CHEMORESISTANCE IN ACUTE MYELOID LEUKEMIA

    … Leukemia (AML) is the most common type of acute hematological malignancy in adults. 40–60% of patients relapse due to the emergence of cellular resistance to anti- leukemic drugs. Drug resistance in leukemic cells has been associated with intratumoral heterogeneity, among which quiescence, …

    milano Repository record for NON-GENETIC MECHANISMS OF CHEMORESISTANCE IN ACUTE MYELOID LEUKEMIA (opens in a new tab)

  13. Determinants of Pharmacodynamic Heterogeneity in Multiple Myeloma Cells

    Multiple myeloma is a complex heterogeneous hematological malignancy comprising of rapidly proliferating genetically diverse clonal plasma cells. Tumor initiation, development, and progression occur through a series of pre-malignant stages, with sequential acquisition of genomic aberrations. The …

    buffalo Repository record for Determinants of Pharmacodynamic Heterogeneity in Multiple Myeloma Cells (opens in a new tab)

  14. Molecular Mechanisms in Differentiation - Induction in Acute Promyelocytic Leukemia.

    Leukemia is a hematological malignancy that is characterized by the clonal expansion of immature hematopoietic cells, which have escaped from the tightly coordinated cell cycle regulation, differentiation and apoptosis controls. In general, leukemia is characterized by a variety of mutations in …

    radboud Repository record for Molecular Mechanisms in Differentiation - Induction in Acute Promyelocytic Leukemia. (opens in a new tab) Download PDF for Molecular Mechanisms in Differentiation - Induction in Acute Promyelocytic Leukemia. (opens in a new tab)

  15. The role of metabolism in the anti-tumor cytotoxicity of natural killer cells

    … have been moderately successful against hematological malignancy, they are less effective against solid cancers. This lack of success partially results from the immunosuppressive effects of the tumor microenvironment (TME). While tumors use myriad processes to evade the immune system, the …

    bu Repository record for The role of metabolism in the anti-tumor cytotoxicity of natural killer cells (opens in a new tab)

  16. Applications of Bayesian Network Models in Studying Acute Myeloid Leukemia (AML)

    … is to identify AML patients from another type of hematological malignancy. I performed the classification of patients using a cross-validation technique and tested the performance on an independent dataset. Moreover, I trained my model on a training dataset with 366 samples and evaluated the …

    texas-state Repository record for Applications of Bayesian Network Models in Studying Acute Myeloid Leukemia (AML) (opens in a new tab)

  17. Novel Treatment of Acute Myeloid Leukemia by Targeting Complex II in the Mitochondrial Electron Transport Chain

    Acute myeloid leukemia (AML) is a hematological malignancy characterized by an increased reliance on mitochondria-related energetic pathways (e.g., oxidative phosphorylation (OXPHOS)); and consistently, complex II (CII) of the mitochondrial electron transport chain has elevated activity in AML, …

    guelph Repository record for Novel Treatment of Acute Myeloid Leukemia by Targeting Complex II in the Mitochondrial Electron Transport Chain (opens in a new tab)

  18. Deregulation of the notch signaling pathway N B-cell chronic lymphocytic leukemia

    … Lymphocytic Leukemia (B-CLL) is the most common hematological malignancy in United States[1], characterized by CD5+ B-lymphocytes in peripheral blood. Deregulation of the Notch signaling pathway has been suggested to contribute to B-CLL pathogenesis [2-4]. Our objective was to characterize the …

    missouri Repository record for Deregulation of the notch signaling pathway N B-cell chronic lymphocytic leukemia (opens in a new tab)

  19. Effect of Psychosocial Factors on Health Outcomes in Autologous BMT Patients

    … autologous transplant (AuBMTs) in patients with hematological malignancies. Participants included 130 cancer patients (51.5% male) who completed a pre-AuBMT evaluation (M = 58.39, SD = 11.71, range = 21 – 80). Data extracted include information regarding measures for distress (DT), problems in …

    ku Repository record for Effect of Psychosocial Factors on Health Outcomes in Autologous BMT Patients (opens in a new tab)

  20. Multi-Niche Human Bone Marrow On-A-Chip for Studying the Interactions of Adoptive Cell Therapies with Multiple Myeloma

    … plasma cells, is the 2nd-most common hematological malignancy. However, despite the advent of immunotherapies like chimeric antigen receptor (CAR) -T cells, which gained FDA approval in March 2021, relapse is nearly universally inevitable. The bone marrow (BM) microenvironment …

    gatech Repository record for Multi-Niche Human Bone Marrow On-A-Chip for Studying the Interactions of Adoptive Cell Therapies with Multiple Myeloma (opens in a new tab)

Page 1 of 4